Daniel R. Tabet

Daniel R. Tabet

Auto-generated profile, based on publicly available information

Daniel R. Tabet

Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2026 in Science
Verified
Journal Article
Closed access
DTDaniel R. Tabet
Daniel R. Tabet
ACAtina G. Coté
Atina G. Coté
MLMegan C. Lancaster
Megan C. Lancaster
JWJochen Weile
Jochen Weile
ARAshyad Rayhan
Ashyad Rayhan
FRFrederick Roth
Frederick Roth
Variants in the familial hypercholesterolemia gene LDLR —the most important genetic driver of cardiovascular disease—can raise circulating low-density lipoprotein (LDL) cholesterol concentrations and increase the risk of premature atherosclerosis. Definitive classifications are lacking for nearly half of clinically encountered LDLR missense variants, limiting interventions that reduce disease burden. We tested the impact of ~17,000 (nearly all possible) LDLR coding variants on both LDLR cell-surface abundance and LDL uptake, yielding sequence–function maps that recapitulate known biochemistry, offer functional insights, and provide evidence for interpreting clinical variants. Functional scores correlated with hyperlipidemia phenotypes in prospective human cohorts and augmented polygenic scores to improve risk inference, highlighting the potential of this resource to accelerate familial hypercholesterolemia diagnosis and improve patient outcomes.

25 August 2026 in Circulation
Verified
Journal Article
Open access
YYYuta Yamamoto
Yuta Yamamoto
KCKaiser Chua
Kaiser Chua
DSDavid Staudt
David Staudt
AFAlexis Ferrasse
Alexis Ferrasse
AKAnna Kirillova
Anna Kirillova
VPVictoria N Parikh
Victoria N Parikh
BACKGROUND: An estimated 1 in 500 people lives with hypertrophic cardiomyopathy (HCM), a disease for which genetic diagnosis can identify family members at risk and increasingly guide therapy. Variants in the MYBPC3 gene, which encodes cardiac myosin-binding protein C (cMyBP-C), account for a significant proportion of HCM cases. However, many of these are classified as variants of uncertain significance, complicating clinical decision-making. Scalable methods for variant interpretation in disease-specific cell types are crucial for understanding variant impact and uncovering disease mechanisms. METHODS: We developed a scaled multidimensional mapping strategy to evaluate the functional impact of variants across a critical domain of cMyBP-C. We incorporate saturation base editing at the native MYBPC3 locus, a long-read RNA sequencing-enabled assay of variant splice effects, and measurements of HCM-relevant phenotypes, including cMyBP-C abundance, hypertrophic signaling, and ubiquitin-proteasome function in human induced pluripotent stem cell–derived cardiomyocytes. RESULTS: Our multidimensional mapping strategy enabled high-resolution functional analysis of MYBPC3 variants in induced pluripotent stem cell–derived cardiomyocytes. Our massively parallel splicing assay identified novel splice-disrupting variants. Targeted transient base editing generated a comprehensive variant library at the native locus, capturing diverse variant effects on cellular HCM-relevant phenotypes. Integration of functional assays revealed that decreased cMyBP-C abundance is a key driver of HCM-related phenotypes. In parallel, downregulation of protein degradation was observed to correlate with MYBPC3 loss of function, and novel potential disease mechanisms were identified for missense variants near a critical binding domain. Bayesian estimates of variant effects enable the reclassification of clinical variants. CONCLUSIONS: This work provides a platform for extending genome engineering in induced pluripotent stem cells to multiplexed assays of variant effects across diverse disease-relevant cellular phenotypes, enhancing our understanding of variant pathogenicity and uncovering novel biological mechanisms that could inform therapeutic strategies.

18 November 2025 in bioRxiv
Verified
Preprint
Open access
AAAnna Axakova
Anna Axakova
ABAmund Holte Berger
Amund Holte Berger
WLWarren van Loggerenberg
Warren van Loggerenberg
NKNishka Kishore
Nishka Kishore
MGMarinella Gebbia
Marinella Gebbia
FRFrederick Roth
Frederick Roth
Pathogenic variants in the Autoimmune Regulator (AIRE) gene cause Autoimmune Polyendocrine Syndrome Type 1 (APS-1), a rare primary immunodeficiency disease with symptoms including hypoparathyroidism, adrenal insufficiency, and chronic mucocutaneous candidiasis. AIRE increases the expression and presentation of tissue-specific genes expressing 'self' antigens in the developing T cell niche, thus triggering the elimination of self-reactive T cells and preventing autoimmunity. Earlier diagnoses can benefit patients, and APS-1 diagnosis by AIRE sequencing is increasingly common. However, two thirds of reported clinical variants are missense, and more than half of these are "variants of uncertain significance" (VUS). Cell-based variant functional assays can provide strong evidence towards more informative variant classification, but these are carried out reactively, often years after clinical presentation. By contrast, proactively assessing all possible missense variants could provide immediate evidence to guide genetic diagnosis, even for never-before-seen variants. Here we used an insulin promoter-driven reporter to proactively assess the function of 9790 AIRE missense variants. The resulting AIRE variant effect map both validates and extends current biochemical knowledge, concords with pathogenicity annotations, and provides proactive evidence for 70% of previously-reported VUS. Placing our map in the context of both an international APS-1 cohort and the UK BioBank revealed quantitative genotype-phenotype correlations. Using current guidelines, we provide classifications for 32% of current VUS. Together, our proactive resource of AIRE variant impacts offers the potential to improve patient outcomes via more rapid and definitive APS-1 diagnosis.

20 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
FBFang (Flora) Bai
Fang (Flora) Bai
KCKaiser Chua
Kaiser Chua
DLDaniel Li
Daniel Li
AKAnna Kirillova
Anna Kirillova
SYSunil Yadav
Sunil Yadav
VPVictoria N Parikh
Victoria N Parikh
The promise of precision therapeutics in genetic cardiomyopathies relies on linking specific therapies to variant mechanisms. Missense variants in the cardiac splice regulator RBM20 cause a highly penetrant and arrhythmogenic dilated cardiomyopathy. Disease-causing variants in RBM20’s arginine-serine rich (RS) domain act via formation of toxic gain of function cytoplasmic granules, but this is not true for a small number of clinically adjudicated pathogenic variants in its glutamate(E)-rich domain. To better define the effects of E-rich domain variants, we developed a scalable screen based on induced pluripotent stem cell (iPSC) cardiomyocyte differentiation that identified several additional damaging variants. Several of these reduced RBM20 protein abundance and stability. We therefore hypothesized that, unlike RS domain variants, these E-rich variants might be rescued by RBM20 overexpression. To test this hypothesis, we generated induced pluripotent stem cells (iPSCs) from a patient with a pathogenic E-rich domain variant (p.E913K), and confirmed reduced RBM20 protein expression in these RBM20 +/p.E913K cells after differentiation to iPSC-derived cardiomyocytes (iPSC-CM, vs. engineered isogenic RBM20 +/+ ). These iPSC-CMs also displayed aberrant transcriptional splicing, reduced contractility, increased calcium-induced calcium release, and nuclear localization of RBM20 protein, often with more than the two expected RBM20- centric splice factories. AAV-based overexpression of RBM20 reversed some, but not all of the mis-splicing events identified in RBM20 +/p.E913K iPSC-CMs, and did not improve their abnormal contractility, calcium handling or supernumerary RBM20 nuclear granules. In summary, our data indicate that pathogenic E-rich domain variants reduce RBM20 protein abundance, but that their mechanism is unlikely to be explained by haploinsufficiency alone.